HER2:
- Percent Cases Positive: 20%
- Methods: Immunohistochemistry, Fluorescence in situ hybridization
- Associated Therapies: Ado-trastuzumab emtansine (Kadcyla), Lapatinib (Tykerb), Neratinib (Nerlynx), Pertuzumab (Perjeta), Trastuzumab (Herceptin)
- Percent Cases Positive: 80% ER / 52% PR (65% of ER+)
- Methods: Immunohistochemistry
- Associated Therapies:
- Hormone Therapies - tamoxifen (Nolvadex, Soltamox), Fulvestrant (Faslodex), Toremifene (Fareston)
- Aromatase Inhibitors (used only in postmenopausal women) - anastrozole (Arimidex), exemestane (Aromasin), and letrozole (Femara
- Hormone Therapies - tamoxifen (Nolvadex, Soltamox), Fulvestrant (Faslodex), Toremifene (Fareston)
- Percent Cases Positive:
- Methods: Immunohistochemistry
- Associated Therapies: nivolumab (Opdivo), pembrolizumab (Keytruda), atezolizumab (Tecentriq), durvalumab (Imfinzi), avelumab (Bavencio)